245 related articles for article (PubMed ID: 10740291)
1. Development and therapeutic potential of kynurenic acid and kynurenine derivatives for neuroprotection.
Stone TW
Trends Pharmacol Sci; 2000 Apr; 21(4):149-54. PubMed ID: 10740291
[TBL] [Abstract][Full Text] [Related]
2. Kynurenic acid antagonists and kynurenine pathway inhibitors.
Stone TW
Expert Opin Investig Drugs; 2001 Apr; 10(4):633-45. PubMed ID: 11281814
[TBL] [Abstract][Full Text] [Related]
3. Ischemic Stroke and Kynurenines: Medicinal Chemistry Aspects.
Hertelendy P; Toldi J; Fülöp F; Vécsei L
Curr Med Chem; 2018; 25(42):5945-5957. PubMed ID: 29532751
[TBL] [Abstract][Full Text] [Related]
4. Modulation of striatal quinolinate neurotoxicity by elevation of endogenous brain kynurenic acid.
Harris CA; Miranda AF; Tanguay JJ; Boegman RJ; Beninger RJ; Jhamandas K
Br J Pharmacol; 1998 May; 124(2):391-9. PubMed ID: 9641558
[TBL] [Abstract][Full Text] [Related]
5. Inhibitors of kynurenine hydroxylase and kynureninase increase cerebral formation of kynurenate and have sedative and anticonvulsant activities.
Carpenedo R; Chiarugi A; Russi P; Lombardi G; Carlà V; Pellicciari R; Mattoli L; Moroni F
Neuroscience; 1994 Jul; 61(2):237-43. PubMed ID: 7969905
[TBL] [Abstract][Full Text] [Related]
6. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease.
Heyes MP; Saito K; Crowley JS; Davis LE; Demitrack MA; Der M; Dilling LA; Elia J; Kruesi MJ; Lackner A
Brain; 1992 Oct; 115 ( Pt 5)():1249-73. PubMed ID: 1422788
[TBL] [Abstract][Full Text] [Related]
7. Enzyme-catalyzed production of the neuroprotective NMDA receptor antagonist 7-chlorokynurenic acid in the rat brain in vivo.
Wu HQ; Salituro FG; Schwarcz R
Eur J Pharmacol; 1997 Jan; 319(1):13-20. PubMed ID: 9030892
[TBL] [Abstract][Full Text] [Related]
8. The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations.
Tan L; Yu JT; Tan L
J Neurol Sci; 2012 Dec; 323(1-2):1-8. PubMed ID: 22939820
[TBL] [Abstract][Full Text] [Related]
9. Kynurenine pathway inhibition as a therapeutic strategy for neuroprotection.
Stone TW; Forrest CM; Darlington LG
FEBS J; 2012 Apr; 279(8):1386-97. PubMed ID: 22248239
[TBL] [Abstract][Full Text] [Related]
10. An expanding range of targets for kynurenine metabolites of tryptophan.
Stone TW; Stoy N; Darlington LG
Trends Pharmacol Sci; 2013 Feb; 34(2):136-43. PubMed ID: 23123095
[TBL] [Abstract][Full Text] [Related]
11. Resistance to kynurenic acid of the NMDA receptor-dependent toxicity of 3-nitropropionic acid and cyanide in cerebellar granule neurons.
Fatokun AA; Smith RA; Stone TW
Brain Res; 2008 Jun; 1215():200-7. PubMed ID: 18486115
[TBL] [Abstract][Full Text] [Related]
12. Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword?
Ostapiuk A; Urbanska EM
CNS Neurosci Ther; 2022 Jan; 28(1):19-35. PubMed ID: 34862742
[TBL] [Abstract][Full Text] [Related]
13. Novel kynurenic acid analogues in the treatment of migraine and neurodegenerative disorders: preclinical studies and pharmaceutical design.
Tajti J; Majlath Z; Szok D; Csati A; Toldi J; Fulop F; Vecsei L
Curr Pharm Des; 2015; 21(17):2250-8. PubMed ID: 25557633
[TBL] [Abstract][Full Text] [Related]
14. Possibility of Amino Acid Treatment to Prevent the Psychiatric Disorders via Modulation of the Production of Tryptophan Metabolite Kynurenic Acid.
Fukuwatari T
Nutrients; 2020 May; 12(5):. PubMed ID: 32414200
[TBL] [Abstract][Full Text] [Related]
15. Protection against quinolinic acid-mediated excitotoxicity in nigrostriatal dopaminergic neurons by endogenous kynurenic acid.
Miranda AF; Boegman RJ; Beninger RJ; Jhamandas K
Neuroscience; 1997 Jun; 78(4):967-75. PubMed ID: 9174065
[TBL] [Abstract][Full Text] [Related]
16. The pharmacological manipulation of glutamate receptors and neuroprotection.
Stone TW; Addae JI
Eur J Pharmacol; 2002 Jul; 447(2-3):285-96. PubMed ID: 12151020
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid levels of kynurenine pathway metabolites in patients with eating disorders: relation to clinical and biochemical variable.
Demitrack MA; Heyes MP; Altemus M; Pigott TA; Gold PW
Biol Psychiatry; 1995 Apr; 37(8):512-20. PubMed ID: 7542489
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders.
Erhardt S; Olsson SK; Engberg G
CNS Drugs; 2009; 23(2):91-101. PubMed ID: 19173370
[TBL] [Abstract][Full Text] [Related]
19. The pentylenetetrazole-induced activity in the hippocampus can be inhibited by the conversion of L-kynurenine to kynurenic acid: an in vitro study.
Rozsa E; Robotka H; Nagy D; Farkas T; Sas K; Vecsei L; Toldi J
Brain Res Bull; 2008 Jul; 76(5):474-9. PubMed ID: 18534254
[TBL] [Abstract][Full Text] [Related]
20. A role for inflammatory metabolites as modulators of the glutamate N-methyl-D-aspartate receptor in depression and suicidality.
Bay-Richter C; Linderholm KR; Lim CK; Samuelsson M; Träskman-Bendz L; Guillemin GJ; Erhardt S; Brundin L
Brain Behav Immun; 2015 Jan; 43():110-7. PubMed ID: 25124710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
